GPCR Archives

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Nov 2016

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in this profitable field at bay. Heptares Therapeutics develops therapies directed to G protein-coupled receptors (GPCRs), a large family of hot but elusive targets for biopharma. The British company, owned by the Japanese Sosei, just announced it […]

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 22 at 1.33.19 PM e1479818165882

News and Trends 25 Nov 2016

Structural Biology meets Drug Discovery in this Cool Company

After an amazing day in Paris for Labiotech Refresh, we head back to Germany to meet Proteros. The company is working non-stop to provide drug candidates against some of the hottest targets in biotech. City: Munich, Germany Founded: 1999 Employees: 80+ Financial data: The company just announced a €157M ($167M) deal with MSD Mission: Proteros’ expertise in structural biology […]

November 25, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 23 Nov 2016

These Biotech Veterans have Launched a Startup to ‘Drug the Undruggable’

GPCRs have spelled “dead end” for many a biotech and academic endeavor. I sat down with Confo Therapeutics to hear about how they’re recruiting antibodies for a new onslaught. Despite their allure as the key to many indications, GPCRs are not a target for the faint of heart because they tend to move through a […]

November 23, 2016 - 4 minutesmins - By Evelyn Warner

heptares allergan neurological alzheimer gpcr

News and Trends 7 Apr 2016

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech

Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer’s, to Allergan for up to €3Bn. A good way for Allergan to ‘get over’ yesterday’s failed Pfizer acquisition. Based in Cambridge, UK, Heptares Therapeutics is creating new therapies with their StaR platform, that allows it to target G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to many […]

April 7, 2016 - 3 minutesmins - By Denise Neves Gameiro

migraine biotech cgrps heptares review neurology

News and Trends 17 Mar 2016

A Relief for Migraines at last? The Biotech race for the Ultimate Cure

A Migraine is more than just a headache; it is a neurological disorder affecting a staggering 10% of the worldwide population. So where are we on fighting a viable therapy – and who is working on Migraines? People of all ages are at risk of migraine, with women being three times more likely to suffer from […]

March 17, 2016 - 4 minutesmins - By Ekaterina Perets

News and Trends 30 Nov 2015

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

Heptares Therapeutics from the UK has landed Pfizer in a huge potential $1.9Bn deal for their G-protein receptor platform. Heptares Therapeutics was founded by Fiona Marshall (one of our Top 10 UK Women in Biotech), who now serves as a CSO to Japanese Big boss Sosei, which wholly acquired Heptares earlier this year in a […]

November 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

The Israeli TEVA and UK Heptares Therapeutics (now owned by Japanese Sosei) have partnered up on novel drug therapies targeting Migraines. The pain and disruption migraines can cause pain that lasts from 4 to 72 hours, and around 10 million worldwide suffer such episodes on a regular basis. Signs and symptoms of a migraine include photosensitivity […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 7 Sep 2015

A reliable technology to develop the next generation of GPCR targeted medicines

You must have heard of GPCRs, or more specifically G protein-coupled receptors. Doesn’t ring a bell? You know, it’s this large protein family of receptors that sense molecules outside the cell and trigger an inside signal. A technology called IP-One could give a large advantage to scientists working on GPCR-targeted drugs. We had the opportunity to […]

September 7, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 10 Aug 2015

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration under which AstraZeneca will acquire exclusive global rights on the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate. Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating […]

August 10, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 31 Jul 2015

MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs

Germany-based MorphoSys AG announced today that its partner Heptares Therapeutics, has initiated a therapeutic antibody program arising from the alliance the companies entered into in February 2013. Heptares will use MorphoSys’s antibody library to generate a new candidate targeting a GPCR, one of the largest class of pharmaceutical target currently on the market. In February 2013, MorphoSys and Heptares […]

July 31, 2015 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

GPCR

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

Structural Biology meets Drug Discovery in this Cool Company

These Biotech Veterans have Launched a Startup to ‘Drug the Undruggable’

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech

A Relief for Migraines at last? The Biotech race for the Ultimate Cure

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

A reliable technology to develop the next generation of GPCR targeted medicines

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!